Liraglutide Injection

A blockbuster drug in the field of diabetes, with a significant hypoglycemic effect

Liraglutide is a human glucagon-like peptide-1[GLP-1]receptor agonist, which promotes insulin secretion based on blood glucose level, protects islet B cells, delays gastric emptying and reduces appetite. As an emerging new drug for diabetes treatment in recent years, it can effectively reduce blood glucose level, with low risk of hypoglycemia, which is indicated for blood glucose control in adult patients with type 2 diabetes.

Indications

Liraglutide Injection is indicated for glycemic control in adults with type 2 diabetes mellitus: To be combined with metformin or a sulfonylurea for use in patients ineffectively controlled on metformin or a sulfonylurea alone at the maximal tolerated dose (MTD).

Strength

3mL: 18mg (pre-filled)